189 related articles for article (PubMed ID: 32850408)
1. p28 Bacterial Peptide, as an Anticancer Agent.
Yaghoubi A; Khazaei M; Avan A; Hasanian SM; Cho WC; Soleimanpour S
Front Oncol; 2020; 10():1303. PubMed ID: 32850408
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Actions of Azurin and Its Derived Peptide p28.
Huang F; Shu Q; Qin Z; Tian J; Su Z; Huang Y; Gao M
Protein J; 2020 Apr; 39(2):182-189. PubMed ID: 32180097
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M
Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.
Jia L; Gorman GS; Coward LU; Noker PE; McCormick D; Horn TL; Harder JB; Muzzio M; Prabhakar B; Ganesh B; Das Gupta TK; Beattie CW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):513-24. PubMed ID: 21085965
[TBL] [Abstract][Full Text] [Related]
5. A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins.
Coppari E; Yamada T; Bizzarri AR; Beattie CW; Cannistraro S
Int J Nanomedicine; 2014; 9():1799-813. PubMed ID: 24748790
[TBL] [Abstract][Full Text] [Related]
6. p28, a first in class peptide inhibitor of cop1 binding to p53.
Yamada T; Christov K; Shilkaitis A; Bratescu L; Green A; Santini S; Bizzarri AR; Cannistraro S; Gupta TK; Beattie CW
Br J Cancer; 2013 Jun; 108(12):2495-504. PubMed ID: 23736031
[TBL] [Abstract][Full Text] [Related]
7. Solution structure of the anticancer p28 peptide in biomimetic medium.
Cantini F; Gianni' P; Savarin P; Bizzarri AR; Sette M
J Pept Sci; 2021 Nov; 27(11):e3357. PubMed ID: 34151482
[TBL] [Abstract][Full Text] [Related]
8. Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.
Bizzarri AR; Santini S; Coppari E; Bucciantini M; Di Agostino S; Yamada T; Beattie CW; Cannistraro S
Int J Nanomedicine; 2011; 6():3011-9. PubMed ID: 22162658
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of bacterial effector protein azurin targeting tumor suppressor p53 and inhibiting its ubiquitination.
Hu J; Jiang W; Zuo J; Shi D; Chen X; Yang X; Zhang W; Ma L; Liu Z; Xing Q
Commun Biol; 2023 Jan; 6(1):59. PubMed ID: 36650277
[TBL] [Abstract][Full Text] [Related]
10. Modelling the interaction between the p53 DNA-binding domain and the p28 peptide fragment of Azurin.
Santini S; Bizzarri AR; Cannistraro S
J Mol Recognit; 2011; 24(6):1043-55. PubMed ID: 22038811
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the anticancer p28 peptide with p53-DBD as studied by fluorescence, FRET, docking and MD simulations.
Bizzarri AR; Moscetti I; Cannistraro S
Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):342-350. PubMed ID: 30419285
[TBL] [Abstract][Full Text] [Related]
12. p28-Mediated Activation of p53 in G2-M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic Chemotherapy.
Yamada T; Das Gupta TK; Beattie CW
Cancer Res; 2016 Apr; 76(8):2354-65. PubMed ID: 26921335
[TBL] [Abstract][Full Text] [Related]
13. Anticancer activity of
Yaghoubi A; Movaqar A; Asgharzadeh F; Derakhshan M; Ghazvini K; Hasanian SM; Avan A; Mostafapour A; Khazaei M; Soleimanpour S
Iran J Basic Med Sci; 2023; 26(7):768-776. PubMed ID: 37396945
[TBL] [Abstract][Full Text] [Related]
14. Noncationic peptides obtained from azurin preferentially enter cancer cells.
Taylor BN; Mehta RR; Yamada T; Lekmine F; Christov K; Chakrabarty AM; Green A; Bratescu L; Shilkaitis A; Beattie CW; Das Gupta TK
Cancer Res; 2009 Jan; 69(2):537-46. PubMed ID: 19147567
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Bacterial Peptide p28 on Viability and Apoptosis Status of P53-null HeLa Cells.
Abuei H; Behzad-Behbahani A; Faghihi F; Farhadi A; Rafiei Dehbidi GR; Pirouzfar M; Zare F
Adv Pharm Bull; 2019 Oct; 9(4):668-673. PubMed ID: 31857973
[No Abstract] [Full Text] [Related]
16. Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.
Gao M; Zhou J; Su Z; Huang Y
Protein Sci; 2017 Dec; 26(12):2334-2341. PubMed ID: 28960574
[TBL] [Abstract][Full Text] [Related]
17. p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation.
Yamada T; Das Gupta TK; Beattie CW
Mol Pharm; 2013 Sep; 10(9):3375-83. PubMed ID: 23952735
[TBL] [Abstract][Full Text] [Related]
18. Binding of Amphipathic Cell Penetrating Peptide p28 to Wild Type and Mutated p53 as studied by Raman, Atomic Force and Surface Plasmon Resonance spectroscopies.
Signorelli S; Santini S; Yamada T; Bizzarri AR; Beattie CW; Cannistraro S
Biochim Biophys Acta Gen Subj; 2017 Apr; 1861(4):910-921. PubMed ID: 28126403
[TBL] [Abstract][Full Text] [Related]
19. A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions.
Mehta RR; Hawthorne M; Peng X; Shilkaitis A; Mehta RG; Beattie CW; Das Gupta TK
Cancer Prev Res (Phila); 2010 Oct; 3(10):1351-60. PubMed ID: 20841487
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma multiforme: novel therapeutic approaches.
Fialho AM; Salunkhe P; Manna S; Mahali S; Chakrabarty AM
ISRN Neurol; 2012; 2012():642345. PubMed ID: 22462021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
